Ana Montero-Pedrazuela

Dr. Ana Montero-Pedrazuela

Alberto Sols Biomedical Research Institute, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2006 in Molecular Psychiatry
Verified
Journal Article
Closed access
AMAna Montero-Pedrazuela
Ana Montero-Pedrazuela
CVCésar Venero
César Venero
RLR Lavado-Autric
R Lavado-Autric
IFI Fernández-Lamo
I Fernández-Lamo
JGJose Manuel García-Verdugo
Jose Manuel García-Verdugo
AGAna Guadaño-Ferraz
Ana Guadaño-Ferraz

31 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EAElvira Alonso-Merino
Elvira Alonso-Merino
RORosa Martín Orozco
Rosa Martín Orozco
LRLidia Ruíz-Llorente
Lidia Ruíz-Llorente
OMOlaia A. Martínez-Iglesias
Olaia A. Martínez-Iglesias
JVJuan Pedro Velasco-Martín
Juan Pedro Velasco-Martín
AAAna Aranda
Ana Aranda
Significance: We show here that binding of the thyroid hormone triiodothyronine to the thyroid hormone receptors (TRs) antagonizes TGF-β/SMAD (mothers against decapentaplegic)-dependent transcription. Transcriptionally inactive TR mutants that do not bind coactivators retained most of the capacity of suppressing transactivation by TGF-β/SMAD, whereas selective mutations in the DNA binding domain abolished this action. TGF-β is a major profibrogenic cytokine, and through this transcriptional mechanism, the hormone-bound TRs act as an endogenous barrier to moderate liver and skin fibrosis. These antagonistic actions on TGF-β/SMAD transcription suggest that TR ligands might be used to block the progression of fibrotic diseases. The natural hormone cannot be used clinically because of severe adverse effects, but novel synthetic ligands with fewer effects might be potentially developed and used.

1 March 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
IBIvan del Barco Barrantes
Ivan del Barco Barrantes
AMAna Montero-Pedrazuela
Ana Montero-Pedrazuela
AGAna Guadaño-Ferraz
Ana Guadaño-Ferraz
MOMaria-Jesus Obregon
Maria-Jesus Obregon
RMRaquel Martinez de Mena
Raquel Martinez de Mena
CNChristof Niehrs
Christof Niehrs
dickkopf (dkk) genes encode a small family of secreted Wnt antagonists, except for dkk3, which is divergent and whose function is poorly understood. Here, we describe the generation and characterization of dkk3 mutant mice. dkk3-deficient mice are viable and fertile. Phenotypic analysis shows no major alterations in organ morphology, physiology, and most clinical chemistry parameters. Since Dkk3 was proposed to function as thyroid hormone binding protein, we have analyzed deiodinase activities, as well as thyroid hormone levels. Mutant mice are euthyroid, and the data do not support a relationship of dkk3 with thyroid hormone metabolism. Altered phenotypes in dkk3 mutant mice were observed in the frequency of NK cells, immunoglobulin M, hemoglobin, and hematocrit levels, as well as lung ventilation. Furthermore, dkk3-deficient mice display hyperactivity.

24 August 2009 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
IFIván Fernández-Lamo
Iván Fernández-Lamo
AMAna Montero-Pedrazuela
Ana Montero-Pedrazuela
JDJosé María Delgado-García
José María Delgado-García
AGAna Guadaño-Ferraz
Ana Guadaño-Ferraz
AGAgnès Gruart
Agnès Gruart

14 November 2019 in Thyroid®
Verified
Journal Article
Closed access
SBSoledad Bárez-López
Soledad Bárez-López
GCGrijota-martinez Carmen
Grijota-martinez Carmen
EAEva Ausó
Eva Ausó
MFMario Fernández-De Frutos
Mario Fernández-De Frutos
AMAna Montero-Pedrazuela
Ana Montero-Pedrazuela
AGAna Guadaño-Ferraz
Ana Guadaño-Ferraz
Background: Mutations in the thyroid hormone (TH) transporter monocarboxylate transporter 8 (MCT8) lead to peripheral hyperthyroidism and profound psychomotor alterations in humans. Mice lacking Mct8 present peripheral hyperthyroidism but no gross neurological abnormalities due to brain compensatory mechanisms involving the enzyme deiodinase type 2 (Dio2). Methods: Here we have analyzed the endocrine and neurologic phenotype of mice lacking both Mct8 and Dio2 at three and six months of age. Thyroxine (T4) and 3,5,3′ triiodothyronine (T3) levels/content were measured by specific radioimmunoassays; motor skill performance was evaluated by the footprint, rotarod, four limb hanging wire, and balance beam tests; and brain histological analysis was performed by immunostaining for neurofilament and parvalbumin. Results: We have found that this mouse model presents peripheral hyperthyroidism and brain hypothyroidism. Interestingly, the severity of the brain hypothyroidism seems permanent and varies across regions, with the striatum being a particularly affected area. We have also found brain alterations at the histological level compatible with TH deficiency and impaired motor skills. Conclusions: These findings indicate the potential of Mct8/Dio2-deficient mice to represent a model for human MCT8 deficiency, to understand the mechanisms underlying its pathophysiology, and ultimately design therapeutic interventions for human patients.

1 October 2017 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
SBSoledad Bárez-López
Soledad Bárez-López
AMAna Montero-Pedrazuela
Ana Montero-Pedrazuela
DBDaniel Bosch-García
Daniel Bosch-García
CVCésar Venero
César Venero
AGAna Guadaño-Ferraz
Ana Guadaño-Ferraz